Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
STORM Therapeutics to Present Data on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at AACR Annual Meeting 2024 | ||
By: PR Newswire Association LLC. - 26 Mar 2024 | Back to overview list |
|
CAMBRIDGE, England, March 26, 2024 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced that Alexandra Sapetschnig, Group Leader at STORM, will present late breaking data on STORM's METTL1 inhibitors at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, held 5-10 April 2024. The presentation entitled 'First-in-class inhibitors of the tRNA methyltransferase METTL1 for the treatment of cancer' details the discovery of STORM's first-in-class inhibitors of METTL1 tRNA methyltransferase and supporting evidence of its potential as a novel target for anti-cancer drugs. Oliver Rausch, Chief Scientific Officer at STORM Therapeutics, said: "We are looking forward to presenting these data on our first-in-class METTL1 inhibitor at the AACR Annual Meeting. As we continue to develop our pipeline of therapies inhibiting RNA modifying enzymes, we are pleased with the progress we are making with METTL1 and are looking forward to advancing this candidate towards clinical development." Details of the late breaking poster presentation are as follow: Poster Title: First-in-class inhibitors of the tRNA methyltransferase METTL1 for the treatment of cancer 1 Storm Therapeutics Ltd, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom Late breaking abstracts will be available in an online itinerary planner here on the 5 April and will be available in on online only supplement to the AACR journal Cancer Research one month after the conference. About STORM Therapeutics STORM has leveraged its first-mover advantage to establish a novel drug discovery and RNA analytics platform leading to the identification of novel targets and a proprietary pipeline of first-in-class small-molecule drug candidates for potential use in oncology, inflammation, viral infection and CNS diseases. The pipeline is exemplified by STORM's METTL3 inhibitor, STC-15, which has received IND approval and commenced its Phase 1 clinical study in cancer patients in November 2022. STC-15 represents the first ever RNA modifying enzyme inhibitor to enter clinical evaluation in humans. Additional programs are planned for advancement into IND-track activities in 2024. STORM investors include M Ventures, Pfizer Ventures, Taiho Ventures LLC, Seroba Life Sciences, Cambridge Innovation Capital I Limited, IP Group plc, UTokyo Innovation Platform Co., Ltd. (UTokyo IPC) and the Fast Track Initiative (FTI). For more information, please visit www.stormtherapeutics.com About STC-15 STC-15 has also been shown preclinically to inhibit tumour growth through mechanisms involving anti-cancer immune responses, such as changes in interferon signalling and synergy with T cell checkpoint blockade. STORM commenced the dosing of the first patient in a Phase 1 clinical study of STC-15 in patients living with solid tumours in November 2022 and anticipates presenting first results from its study in 2024. Details of the study can be found on clinicaltrials.gov under the identifier NCT05584111. About AACR View original content:https://www.prnewswire.com/news-releases/storm-therapeutics-to-present-data-on-its-first-in-class-mettl1-trna-methyltransferase-inhibitors-at-aacr-annual-meeting-2024-302098685.html SOURCE STORM Therapeutics Ltd |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |